Advertisement

The current and emerging therapeutic approaches in drug-resistant epilepsy management

  • Amir Mehdizadeh
  • Mohammad Barzegar
  • Sohrab Negargar
  • Azita Yahyavi
  • Sina RaeisiEmail author
Review article
  • 36 Downloads

Abstract

Epilepsy is a neurologic disorder consisting of recurrent spontaneous seizures. Antiepileptic drugs administration is the most commonly used therapeutic strategy in the management of epilepsy. However, 20–30% of epilepsy patients have seizure episodes that are not controlled by these medicines (drug-resistant epilepsy). The management of drug-resistant epilepsy, especially in the children, is challenging and can cause economic and social problems, and lower the patients’ quality of life, cognition, and mood. Several therapeutic approaches for drug-resistant epilepsy are available including surgical methods, neurostimulation treatments, and diet therapies which lead to diminishing the epileptic seizures. An increasing number of novel and potential therapeutic approaches such as gene therapy, gene editing, cell therapy, exosome therapy, and molecular network targeting have also been explored. The present study is aimed to review these current and emerging therapeutic approaches for drug-resistant epilepsy.

Keywords

Drug-resistant epilepsy Surgery Diet therapy Gene therapy Cell therapy Exosome therapy 

Notes

Acknowledgements

This work was supported by Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Hodges SL, Lugo JN (2018) Wnt/β-catenin signaling as a potential target for novel epilepsy therapies. Epilepsy Res 146:9–16Google Scholar
  2. 2.
    Nunes ML, Appel CC, da Costa JC (2003) Apparent life-threatening episodes as the first manifestation of epilepsy. Clin Pediatr 42(1):19–22Google Scholar
  3. 3.
    Barzegar M, Mahdavi M, Behbehani AG, Tabrizi A (2015) Refractory convulsive status epilepticus in children: etiology, associated risk factors and outcome. Iran J Child Neurol 9(4):24Google Scholar
  4. 4.
    Papandreou D, Pavlou E, Kalimeri E, Mavromichalis I (2006) The ketogenic diet in children with epilepsy. Br J Nutr 95(1):5–13Google Scholar
  5. 5.
    Cunnane S, Musa K, Ryan M, Whiting S, Fraser D (2002) Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 67(2–3):131–135Google Scholar
  6. 6.
    Giussani G, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E (2014) Prevalence and incidence of epilepsy in Italy based on a nationwide database. Neuroepidemiology 43(3–4):228–232Google Scholar
  7. 7.
    Lauritzen F, Eid T, Bergersen LH (2015) Monocarboxylate transporters in temporal lobe epilepsy: roles of lactate and ketogenic diet. Brain Struct Funct 220(1):1–12Google Scholar
  8. 8.
    Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH (2008) Epilepsy surveillance among adults–19 states, behavioral risk factor surveillance system, 2005. MMWR Surveill Summ 57(6):1–20Google Scholar
  9. 9.
    Mohanraj R, Brodie M (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13(3):277–282Google Scholar
  10. 10.
    Campos G, Fortuna A, Falcão A, Alves G (2018) In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res 146:63–86Google Scholar
  11. 11.
    Liu X, Han Q (2015) Risk factors on health-related quality of life in children with epilepsy. Clin Pediatr 54(14):1334–1338Google Scholar
  12. 12.
    Valizadeh L, Barzegar M, Akbarbegloo M, Zamanzadeh V, Rahiminia E, Ferguson C (2013) The relationship between psychosocial care and attitudes toward illness in adolescents with epilepsy. Epilepsy Behav 27(1):267–271Google Scholar
  13. 13.
    Cottrell L, Khan A (2005) Impact of childhood epilepsy on maternal sleep and socioemotional functioning. Clin Pediatr 44(7):613–616Google Scholar
  14. 14.
    Boison D (2007) Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 5(2):115–125Google Scholar
  15. 15.
    Sørensen AT, Kokaia M (2013) Novel approaches to epilepsy treatment. Epilepsia 54(1):1–10Google Scholar
  16. 16.
    Dalic L, Cook MJ (2016) Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat 12:2605–2616Google Scholar
  17. 17.
    Rosenow F, Lüders H (2001) Presurgical evaluation of epilepsy. Brain 124(9):1683–1700Google Scholar
  18. 18.
    Prideaux L, Barton S, Maixner W, Harvey AS (2018) Potential delays in referral and assessment for epilepsy surgery in children with drug-resistant, early-onset epilepsy. Epilepsy Res 143:20–26Google Scholar
  19. 19.
    Lukmanji S, Altura KC, Rydenhag B, Malmgren K, Wiebe S, Jetté N (2018) Accuracy of an online tool to assess appropriateness for an epilepsy surgery evaluation–A population-based Swedish study. Epilepsy Res 145:140–144Google Scholar
  20. 20.
    Ventureyra EC, Higgins MJ (1993) Complications of epilepsy surgery in children and adolescents. Pediatr Neurosurg 19(1):40–56Google Scholar
  21. 21.
    Olson DM (2001) Evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(3):159–165Google Scholar
  22. 22.
    Nordli DR, Kelley KR (2001) Selection and evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(1):1–12Google Scholar
  23. 23.
    Pati S, Alexopoulos AV (2010) Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 77(7):457–567Google Scholar
  24. 24.
    Rajesh P, Bejoy T, VS CP, Kesavadas C, Ashalatha R, Aley A (2018) Hippocampal activations in mesial temporal lobe epilepsy due to hippocampal sclerosis-an observational study on intramural encoding-delayed recall paradigms using task-based memory fMRI. Epilepsy Res 145:31–39Google Scholar
  25. 25.
    Schusse CM, Smith K, Drees C (2018) Outcomes after hemispherectomy in adult patients with intractable epilepsy: institutional experience and systematic review of the literature. J Neurosurg 128(3):853–861Google Scholar
  26. 26.
    Griessenauer CJ, Salam S, Hendrix P, Patel DM, Tubbs RS, Blount JP, Winkler PA (2015) Hemispherectomy for treatment of refractory epilepsy in the pediatric age group: a systematic review. J Neurosurg Pediatr 15(1):34–44Google Scholar
  27. 27.
    Beleza P (2009) Refractory epilepsy: a clinically oriented review. Eur Neuro 62(2):65–71Google Scholar
  28. 28.
    Panebianco M, Rigby A, Weston J, Marson AG (2015) Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev 3(4):CD002896Google Scholar
  29. 29.
    Ben-Menachem E, Revesz D, Simon B, Silberstein S (2015) Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. Eur J Neurol 22(9):1260–1268Google Scholar
  30. 30.
    Finetti C (2015) P90. Transcutaneous vagus nerve stimulation (t-VNS) in a child with dravet syndrome–a case report. Clin Neurophysiol 126(8):e147Google Scholar
  31. 31.
    Amar AP, Levy ML, McComb JG, Apuzzo ML (2001) Vagus nerve stimulation for control of intractable seizures in childhood. Pediatr Neurosurg 34(4):218–223Google Scholar
  32. 32.
    Schulze-Bonhage A (2017) Brain stimulation as a neuromodulatory epilepsy therapy. Seizure 44:169–175Google Scholar
  33. 33.
    Wilder R (1921) The effects of ketonemia on the course of epilepsy. In Mayo Clin Proc 2:307–308Google Scholar
  34. 34.
    Bough K (2008) Energy metabolism as part of the anticonvulsant mechanism of the ketogenic diet. Epilepsia 49(s8):91–93Google Scholar
  35. 35.
    Gonzalez FL, Osorio XR, Rein AG-N, Martinez MC, Fernandez JS, Haba VV, Pedraza AD, Cerdá JM (2015) Drug-resistant epilepsy: definition and treatment alternatives. Neurologia 30(7):439–446Google Scholar
  36. 36.
    Rezaei S, Kavoosi M, Badv RS, Mohammadi M, Zamani GR, Ashrafi MR, Yekaninejad MS, Mahmoudi M, Crossen K, Tehranian A (2017) The influence of ketogenic diet on liver function in children and adolescents with intractable epilepsy. J Compr Pediatr 8(3):e12609Google Scholar
  37. 37.
    Kossoff EH, Shields WD (2014) Nonpharmacologic care for patients with Lennox-Gastaut syndrome: Ketogenic diets and vagus nerve stimulation. Epilepsia 55(s4):29–33Google Scholar
  38. 38.
    Spulber G, Spulber S, Hagenäs L, Åmark P, Dahlin M (2009) Growth dependence on insulin-like growth factor-1 during the ketogenic diet. Epilepsia 50(2):297–303Google Scholar
  39. 39.
    Hartman AL, Gasior M, Vining EP, Rogawski MA (2007) The neuropharmacology of the ketogenic diet. Pediatr Neurol 36(5):281–292Google Scholar
  40. 40.
    Miranda MJ, Turner Z, Magrath G (2012) Alternative diets to the classical ketogenic diet—Can we be more liberal? Epilepsy Res 100(3):278–285Google Scholar
  41. 41.
    Katyal NG, Koehler AN, McGhee B, Foley CM, Crumrine PK (2000) The ketogenic diet in refractory epilepsy: the experience of Children’s Hospital of Pittsburgh. Clin Pediatr 39(3):153–159Google Scholar
  42. 42.
    Milder J, Patel M (2012) Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 100(3):295–303Google Scholar
  43. 43.
    Sudha K, Rao AV, Rao A (2001) Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 303(1–2):19–24Google Scholar
  44. 44.
    Shin E-J, Jeong JH, Chung YH, Kim W-K, Ko K-H, Bach J-H, Hong J-S, Yoneda Y, Kim H-C (2011) Role of oxidative stress in epileptic seizures. Neurochem Int 59(2):122–137Google Scholar
  45. 45.
    Rao G, Mashkouri S, Aum D, Marcet P, Borlongan CV (2017) Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms. Neuropsychiatr Dis Treat 13:585–596Google Scholar
  46. 46.
    Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ (2013) Progress in gene therapy for neurological disorders. Nat Rev Neuro 9(5):277–291Google Scholar
  47. 47.
    Simonato M (2014) Gene therapy for epilepsy. Epilepsy Behav 38:125–130Google Scholar
  48. 48.
    Riban V, Fitzsimons HL, During MJ (2009) Gene therapy in epilepsy. Epilepsia 50(1):24–32Google Scholar
  49. 49.
    Noè F, Pool A-H, Nissinen J, Gobbi M, Bland R, Rizzi M, Balducci C, Ferraguti F, Sperk G, During MJ (2008) Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131(6):1506–1515Google Scholar
  50. 50.
    Raol YH, Lund IV, Bandyopadhyay S, Zhang G, Roberts DS, Wolfe JH, Russek SJ, Brooks-Kayal AR (2006) Enhancing GABAA receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 26(44):11342–11346Google Scholar
  51. 51.
    Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9(8):1076–1080Google Scholar
  52. 52.
    Richichi C, Lin E-JD, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24(12):3051–3059Google Scholar
  53. 53.
    Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M (2007) Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther 15(6):1106–1113Google Scholar
  54. 54.
    Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P, Marzola A, Mora GN, Fabene PF, Simonato M (2011) Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52(3):572–578Google Scholar
  55. 55.
    Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Mora GN (2009) Localized delivery of fibroblast growth factor–2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA 106(17):7191–7196Google Scholar
  56. 56.
    Mollanoori H, Teimourian S (2018) Therapeutic applications of CRISPR/Cas9 system in gene therapy. Biotechnol Lett 40:907–914Google Scholar
  57. 57.
    Savić N, Schwank G (2016) Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168:15–21Google Scholar
  58. 58.
    Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821Google Scholar
  59. 59.
    Wykes R, Lignani G (2018) Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology 132:108–117Google Scholar
  60. 60.
    Incontro S, Asensio CS, Edwards RH, Nicoll RA (2014) Efficient, complete deletion of synaptic proteins using CRISPR. Neuron 83(5):1051–1057Google Scholar
  61. 61.
    Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33(1):102–106Google Scholar
  62. 62.
    Straub C, Granger AJ, Saulnier JL, Sabatini BL (2014) CRISPR/Cas9-mediated gene knock-down in post-mitotic neurons. PloS One 9(8):e105584Google Scholar
  63. 63.
    Rossi F, Cattaneo E (2002) Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci 3(5):401Google Scholar
  64. 64.
    Luarte A, Bátiz LF, Wyneken U, Lafourcade C (2016) Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche. Stem Cells Int 2016:5736059Google Scholar
  65. 65.
    Edgar JR (2016) Q&A: what are exosomes, exactly? BMC Biol 14(1):46Google Scholar
  66. 66.
    Kalani A, Tyagi A, Tyagi N (2014) Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol 49(1):590–600Google Scholar
  67. 67.
    van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213–228Google Scholar
  68. 68.
    Tiwari D, Peariso K, Gross C (2018) MicroRNA-induced silencing in epilepsy: opportunities and challenges for clinical application. Dev Dyn 247(1):94–110Google Scholar
  69. 69.
    Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JH, Schorge S, Lamottke K, Rosenow F (2016) MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol 15(13):1368–1376Google Scholar
  70. 70.
    Ostendorf AP, Wong M (2015) mTOR inhibition in epilepsy: rationale and clinical perspectives. CNS Drugs 29(2):91–99Google Scholar
  71. 71.
    Zeng L-H, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29(21):6964–6972Google Scholar
  72. 72.
    Xiao Z, Peng J, Gan N, Arafat A, Yin F (2016) Interleukin-1β plays a pivotal role via the PI3K/Akt/mTOR signaling pathway in the chronicity of mesial temporal lobe epilepsy. Neuroimmunomodulation 23(5–6):332–344Google Scholar
  73. 73.
    Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74(5):679–687Google Scholar
  74. 74.
    Qu Z, Su F, Qi X, Sun J, Wang H, Qiao Z, Zhao H, Zhu Y (2017) Wnt/β-catenin signalling pathway mediated aberrant hippocampal neurogenesis in kainic acid-induced epilepsy. Cell Biochem Funct 35(7):472–476Google Scholar
  75. 75.
    Engel J (2014) Approaches to refractory epilepsy. Ann Indian Acad Neurol 17:S12–S17Google Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  1. 1.Endocrine Research CenterTabriz University of Medical SciencesTabrizIran
  2. 2.Pediatric Health Research CenterTabriz University of Medical SciencesTabrizIran
  3. 3.Cardiovascular Research CenterTabriz University of Medical SciencesTabrizIran
  4. 4.Department of Anesthesia, Shohada HospitalTabriz University of Medical SciencesTabrizIran

Personalised recommendations